Screener
CG Oncology CGON Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
| Assets | June 30, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Total liabilities | 56,537 | 38,990 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value per share; 700,000,000 and 700,000,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively; 88,306,390 and 80,689,128 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 9 | 8 |
| Additional paid-in capital | 1,547,343 | 1,131,570 |
| Accumulated deficit | (518,234) | (378,976) |
| Total stockholders' equity | 1,029,118 | 752,602 |
| Total liabilities and stockholders' equity | $1,085,655 | $791,592 |
Item 1. Financial Statements.
FAQ
- What is CG Oncology's total liabilities & equity?
- CG Oncology (CGON) reported total liabilities & equity of $1.09B in Q2 2026.
- How has CG Oncology's total liabilities & equity changed year-over-year?
- CG Oncology's total liabilities & equity increased by 54.8% year-over-year, from $701.45M to $1.09B.
- What is the long-term trend for CG Oncology's total liabilities & equity?
- Over 2 years (2023 to 2025), CG Oncology's total liabilities & equity has grown at a 99.3% compound annual growth rate (CAGR), from $199.3M to $791.59M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about CG Oncology's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude